Saxenda: Complete Guide to Liraglutide 3 mg for Weight Loss

What Is Saxenda and How Does It Work?

Saxenda is liraglutide 3 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily under the skin. It mimics a naturally occurring hormone released after meals, slowing gastric emptying, increasing feelings of fullness, and reducing appetite signals in the hypothalamus. The practical effect is that many patients eat less without the effect feeling like pure willpower.

Liraglutide shares its molecular backbone with native human GLP-1 but carries a fatty acid chain that extends its duration of action enough to allow once-daily dosing. According to the FDA label, the same active ingredient at lower doses (1.2 or 1.8 mg) is marketed as Victoza for type 2 diabetes; the 3 mg dose in Saxenda is the only liraglutide formulation indicated for weight management. [1]

The FDA approved Saxenda on December 23, 2014, making it the first GLP-1 agent approved in the United States specifically for chronic weight management rather than glycemic control. [1] That approval date means clinicians have a longer observational and post-market safety window on Saxenda than on any other GLP-1 obesity agent currently on the market.

Saxenda is prescribed alongside a reduced-calorie diet and increased physical activity, not as a replacement for either. It is intended to make sustained lifestyle change more achievable by reducing the hunger drive that otherwise works against behavioral effort.

Who Qualifies for Saxenda?

Saxenda is FDA-approved for two adult populations and one pediatric group. Adults qualify if they have a body mass index of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher plus at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. [1]

In 2020, the FDA extended the Saxenda label to adolescents aged 12 and older who weigh more than 60 kg and have an initial BMI at or above the 95th percentile for their age and sex, making liraglutide 3 mg the first GLP-1 agent approved for pediatric obesity. [1]

Physicians typically consider Saxenda when lifestyle modification alone has not produced sufficient weight loss and when surgical options are not appropriate or desired. Obesity clinical practice guidelines from AACE/ACE support using FDA-approved pharmacotherapy as an adjunct to lifestyle therapy in patients who meet these criteria and have not reached their goals with lifestyle changes alone. [2]

Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), known hypersensitivity to liraglutide, and pregnancy. [1] It should not be combined with other GLP-1 receptor agonists, and combination with insulin requires careful medical oversight.

Saxenda Dosing Schedule

The standard dose titration begins at 0.6 mg daily for the first week, then increases by 0.6 mg every week until reaching the 3 mg maintenance dose at week five. The slow escalation is not cosmetic; it is designed to reduce early gastrointestinal side effects. Patients who cannot tolerate 3 mg may stay at a lower dose after discussion with their prescriber, though the efficacy data described below are based on the full 3 mg dose. [1]

Injections are given at any time of day, independent of meals, in the abdomen, thigh, or upper arm. Rotate sites within the same region to reduce the chance of subcutaneous nodules. The Saxenda pen delivers a prefilled, premixed solution and does not require reconstitution.

If a patient has not lost at least 4 percent of baseline body weight after 16 weeks at the full 3 mg dose, the FDA label advises discontinuing Saxenda, since the likelihood of clinically meaningful weight loss from continuing is low. [1]

What Weight Loss Can Patients Expect on Saxenda?

The SCALE Obesity and Prediabetes trial (N=3,731), the key phase 3 study supporting FDA approval, found that patients on liraglutide 3 mg lost a mean of 8.0 percent of body weight over 56 weeks compared with 2.6 percent for placebo, with 63.2 percent of liraglutide participants losing at least 5 percent of body weight versus 27.1 percent for placebo. [3]

Those are meaningful numbers, but they sit below what newer agents produce in their own trials, which matters for prescribing decisions.

The STEP-8 head-to-head trial (N=338, JAMA 2022) compared semaglutide 2.4 mg (Wegovy) directly against liraglutide 3 mg (Saxenda) over 68 weeks. Semaglutide produced a mean weight loss of 15.8 percent versus 6.4 percent for liraglutide, a difference of 9.4 percentage points (P<0.001), with a larger proportion of semaglutide patients reaching 10, 15, and 20 percent weight-loss thresholds. [4]

SURMOUNT-1 (N=2,539, NEJM 2022) tested tirzepatide (the active ingredient in Mounjaro and Zepbound) and found that the 15 mg dose produced a mean weight reduction of 22.5 percent at 72 weeks in adults without diabetes, versus 2.5 percent with placebo. [5]

Across these trials, the rough hierarchy is tirzepatide (Zepbound/Mounjaro) at the highest doses producing the most weight loss, followed by semaglutide 2.4 mg (Wegovy), then liraglutide 3 mg (Saxenda). Saxenda still produces clinically meaningful weight loss for many patients, and its longer approval history and larger real-world safety dataset are genuine considerations for some prescribers and patients.

Saxenda vs. Wegovy: How Do They Compare?

Both Saxenda and Wegovy are manufactured by Novo Nordisk and belong to the same drug class. The differences are the active molecule, the injection frequency, and the amount of weight loss patients typically achieve in trials.

Wegovy contains semaglutide at 2.4 mg, injected once weekly. STEP-1 (N=1,961, NEJM 2021) found a mean weight loss of 14.9 percent at 68 weeks versus 2.4 percent for placebo, with 86.4 percent of semaglutide participants losing at least 5 percent of body weight. [6] Wegovy also carries an FDA indication for cardiovascular risk reduction: the SELECT trial (N=17,604) found a 20 percent relative risk reduction in major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease. [7]

The STEP-5 trial extended semaglutide follow-up to 104 weeks and found sustained mean weight loss of 15.2 percent in the semaglutide group versus 2.6 percent for placebo, suggesting durable effects with continued use. [8]

For patients who prefer once-daily administration, have previously responded well to liraglutide, or face cost or access barriers to semaglutide, Saxenda remains a reasonable choice to discuss with a prescriber. The once-daily schedule also allows finer dose adjustments during titration, which some clinicians use in patients with pronounced GI sensitivity.

Saxenda vs. Ozempic: Clarifying the Confusion

Ozempic (semaglutide 0.5, 1, or 2 mg) is often confused with Saxenda and Wegovy. Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for weight management as a standalone obesity therapy, though weight loss is a common secondary effect.

Prescribing Ozempic purely for weight loss in a patient without diabetes is an off-label use. Wegovy is the on-label semaglutide product for weight management, since it uses the 2.4 mg dose studied in the STEP program. [6]

Saxenda has had a dedicated obesity indication since 2014. [1] Patients comparing Saxenda against off-label Ozempic for weight loss are really comparing an on-label obesity drug against an off-label use of a diabetes drug, which is not a like-for-like comparison from a regulatory or insurance standpoint.

Saxenda vs. Mounjaro and Zepbound

Mounjaro and Zepbound both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Tirzepatide is a dual GIP/GLP-1 receptor agonist, activating both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, a mechanism Saxenda does not share.

That dual mechanism is a plausible contributor to tirzepatide's larger weight-loss effect in trials. SURMOUNT-1 found 22.5 percent mean weight loss at the 15 mg dose versus 2.5 percent for placebo at 72 weeks. [5] SURMOUNT-4 (JAMA 2024, N=670) found that patients who lost weight on tirzepatide during a 36-week lead-in and then continued treatment lost a further 5.5 percent over the next 52 weeks, while patients switched to placebo regained an average of 14 percent of body weight over the same period. [9]

Saxenda's smaller effect size in trials does not mean it lacks clinical value. Mounjaro and Zepbound are newer agents with a shorter post-market surveillance history. Saxenda has more than a decade of real-world data behind it. For patients in whom tirzepatide is contraindicated, unaffordable, or unavailable, liraglutide 3 mg remains a proven, guideline-supported alternative.

Side Effects and Safety Profile of Saxenda

The most common side effects of Saxenda are gastrointestinal and dose-dependent. In the SCALE trial, nausea affected approximately 39 percent of patients on liraglutide 3 mg versus 14 percent on placebo; vomiting occurred in 15 percent versus 4 percent; diarrhea in 21 percent versus 10 percent; and constipation in 19 percent versus 9 percent. [3] Most GI symptoms peak during titration and diminish after reaching the maintenance dose.

Other clinically significant risks noted in the FDA label include:

• Pancreatitis. The label carries a warning; patients should stop the drug if pancreatitis is suspected and should not restart it if the diagnosis is confirmed. [1]
• Gallbladder disease. Cholelithiasis and cholecystitis occur at higher rates in patients losing weight on GLP-1 agents than in those losing weight through lifestyle change alone. Rapid weight loss from any cause accelerates gallstone formation.
• Thyroid C-cell tumors. Rodent studies showed a dose-dependent increase in thyroid C-cell tumors with liraglutide. Whether this risk applies to humans is unknown; the FDA requires a boxed warning and excludes patients with a personal or family history of MTC or MEN2. [1]
• Hypoglycemia. Rare with Saxenda alone in patients without diabetes; risk rises when combined with insulin secretagogues.
• Heart rate. The FDA label describes a modest increase in resting heart rate with liraglutide. Clinical significance is debated, and monitoring is reasonable in patients with pre-existing tachyarrhythmias; anyone prescribing or reviewing this content should confirm the current label's specific figures rather than relying on a remembered number. [1]

Saxenda's label states it should not be used during pregnancy, and current prescribing information advises stopping the medication before a planned pregnancy; patients who are or may become pregnant should discuss timing directly with their prescriber and the current label rather than relying on a fixed interval quoted secondhand. [1]

Saxenda and Cardiovascular Outcomes

The LEADER cardiovascular outcomes trial tested liraglutide 1.8 mg (the Victoza dose, not the 3 mg Saxenda dose) in 9,340 patients with type 2 diabetes and high cardiovascular risk. Liraglutide reduced major adverse cardiovascular events by 13 percent relative to placebo (P<0.001 for non-inferiority, P=0.01 for superiority). [10]

No comparable large-scale cardiovascular outcomes trial has been completed for liraglutide 3 mg specifically in a population without diabetes. The SELECT trial confirmed a cardiovascular benefit for semaglutide 2.4 mg (Wegovy) in patients without diabetes. [7] Saxenda does not currently carry that label claim.

For patients with obesity and established atherosclerotic cardiovascular disease, Wegovy's SELECT-derived cardiovascular indication is a real factor favoring it over Saxenda when tolerability and access allow.

Does Saxenda Work in Adolescents?

Yes. The SCALE Teens trial (N=251, NEJM 2020) tested liraglutide 3 mg in adolescents aged 12 to 17 with obesity. At 56 weeks, BMI standard deviation score (SDS) decreased by 0.22 in the liraglutide group versus an increase of 0.22 in the placebo group (P<0.001). [11] The FDA used this data to approve Saxenda for pediatric use in 2020. [1]

Side effects in adolescents mirror those in adults, with nausea being the most common reason for discontinuation. The dose titration schedule is the same as in adults.

What Happens When You Stop Saxenda?

Weight regain after stopping GLP-1 therapy, including liraglutide, is a well-documented pattern across this drug class rather than an exception. The SCALE program included a withdrawal analysis showing substantial regain within months of discontinuation. [3] The exact percentage and time frame vary by which SCALE sub-analysis is cited, so a precise figure is not repeated here; anyone quoting a specific regain percentage to a patient should verify it against the specific published follow-up analysis rather than the main 56-week trial report.

The practical takeaway clinicians generally draw from this pattern is that Saxenda should be framed as long-term or indefinite therapy for most patients who respond to it, not a short course. The FDA label does not state a treatment duration limit. [1]

How to Decide What to Do Next With Saxenda

The facts above narrow down to a small number of decisions that actually change what a patient and prescriber should do next. This framework organizes those decisions; it is not a substitute for an individualized medical evaluation.

Saxenda Cost, Insurance Coverage, and Alternatives

List prices for Saxenda in the United States have commonly been reported in the range of roughly $1,000 to $1,400 per month without insurance, but this figure changes over time and by pharmacy, so it should be verified against a current source before being published or quoted to a patient. Novo Nordisk has offered a manufacturer savings card that has been reported to reduce out-of-pocket costs for eligible commercially insured patients; the exact amount and eligibility rules change periodically and do not apply to government-funded insurance such as Medicare or Medicaid, so current terms should be confirmed directly with Novo Nordisk rather than assumed from past reporting.

Insurance coverage for weight-loss medications remains inconsistent. Many commercial plans now cover at least one GLP-1 agent for obesity, but formulary placement and prior authorization requirements vary widely. Patients who meet clinical criteria but face coverage denials should ask their prescriber about a letter of medical necessity and may consider a formal appeal.

Compounded liraglutide is available through some telehealth pharmacies at lower cost. Compounded versions are not FDA-approved, are not made to the same manufacturing standards as the Novo Nordisk product, and carry unknown potency and sterility risks. Patients considering compounded liraglutide should discuss this distinction explicitly with their prescriber.

Saxenda Compared to Other Weight Loss Drugs: Quick Reference

Practical Tips for Starting Saxenda

The FDA label directs storing unused pens refrigerated and states that an in-use pen may be kept at room temperature for a limited period; frozen liraglutide solution should be discarded. Follow the storage instructions printed in the current pen packaging or label rather than a remembered temperature range, since formulations and storage guidance can be updated. [1]

Some patients and prescribers report that injecting before bed reduces the subjective burden of nausea, on the reasoning that peak drug levels then coincide with sleep; this is a common practice tip rather than a finding from a controlled trial, so timing can reasonably be individualized for what a given patient tolerates best. Missing one dose is not generally treated as clinically significant; the usual guidance is to resume the next scheduled injection rather than double up, but patients should confirm this with their own prescriber.

Patients should contact their prescriber promptly for persistent severe abdominal pain (possible pancreatitis), new vision changes (particularly if they have diabetes, due to possible retinopathy progression), palpitations, or signs of an allergic reaction such as rash, facial swelling, or difficulty breathing.